clinical trial · NCT05960240
Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.
Chronic Hepatitis bAB-101PlaceboNucleos(t)ide Analogue
brief summary
This three-part, Phase 1 protocol will be the first clinical study of AB-101. Parts 1 and 2 will be a Phase 1a SAD/MAD of AB-101 in healthy adult subjects. Part 3 will be a Phase 1b dose-ranging assessment of AB-101 in non-cirrhotic Chronic Hepatitis B (CHB) subjects.
started
Aug 30, 2023
primary completion
Dec 4, 2025
completion
Feb 9, 2026
last updated
Apr 13, 2026
official title
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, PK and PD of AB-101, an Oral PD-L1 Inhibitor, in Healthy Subjects and Subjects With Chronic HBV Infection.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol